Cargando…

Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant

INTRODUCTION: Disorders of glucose metabolism are a serious acromegaly comorbidity and may be differently impacted by medical treatments of acromegaly. In this retrospective longitudinal multicenter study, we investigated the outcome of glucose metabolism and its predictors in patients treated with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiloiro, Sabrina, Giampietro, Antonella, Visconti, Felicia, Rossi, Laura, Donfrancesco, Federico, Fleseriu, Cara M., Mirra, Federica, Pontecorvi, Alfredo, Giustina, Andrea, Fleseriu, Maria, De Marinis, Laura, Bianchi, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325668/ https://www.ncbi.nlm.nih.gov/pubmed/33907985 http://dx.doi.org/10.1007/s12020-021-02711-3

Ejemplares similares

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

SUN-LB075 Effects of Pegvisomant and Pasireotide LAR on Incidence of Vertebral Fractures in Patients with Acromegaly Resistant to Treatment with First-Line Somatostatin Analogs
por: Chiloiro, Sabrina, et al.
Publicado: (2019)

Pasireotide: a novel treatment for patients with acromegaly
por: Cuevas-Ramos, Daniel, et al.
Publicado: (2016)

Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study
por: Lasolle, Hélène, et al.
Publicado: (2019)

Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation
por: Stelmachowska-Banaś, Maria, et al.
Publicado: (2021)

Resolution of Cyclicity After Pasireotide LAR in a Patient With Cushing Disease
por: Machado, Márcio Carlos, et al.
Publicado: (2021)

Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR
por: Wolf, Peter, et al.
Publicado: (2022)

Risk factors and management of pasireotide-associated hyperglycemia in acromegaly
por: Gadelha, Mônica R, et al.
Publicado: (2020)

Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study
por: Colao, Annamaria, et al.
Publicado: (2020)

Successful Control of Hypoglycemia with Pasireotide LAR in a Patient with Inappropriate Insulin Secretion
por: Rouland, Alexia, et al.
Publicado: (2021)

AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients
por: Daly, Adrian F, et al.
Publicado: (2019)

The Effect of 6 Months’ Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings
por: Witek, Przemysław, et al.
Publicado: (2021)

Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma
por: Feun, Lynn G, et al.
Publicado: (2018)

Pasireotide in the Personalized Treatment of Acromegaly
por: Puig-Domingo, Manel, et al.
Publicado: (2021)

Real-World Experience With Pasireotide Lar in Acromegaly Resistant to First-Generation Somatostatin Analogs: A Single Center 1-Year Observation
por: Stelmachowska-Banas, Maria, et al.
Publicado: (2021)

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
por: Colao, A., et al.
Publicado: (2014)

Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly
por: Schmid, Herbert A., et al.
Publicado: (2016)

Monitoring Patient Improvement Parameters following Pasireotide Treatment in Cushing's Disease
por: Yedinak, Chris, et al.
Publicado: (2013)

Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study
por: Sheppard, Michael, et al.
Publicado: (2014)

Pegvisomant in acromegaly: an update
por: Giustina, A., et al.
Publicado: (2017)

Erratum to: Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study
por: Sheppard, Michael, et al.
Publicado: (2015)

Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly
por: Silverstein, Julie M.
Publicado: (2016)

Safety and tolerability of pasireotide long-acting release in acromegaly—results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study
por: Fleseriu, Maria, et al.
Publicado: (2016)

Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide
por: Puglisi, Soraya, et al.
Publicado: (2020)

Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline
por: Giustina, A., et al.
Publicado: (2014)

Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report
por: Ciresi, A., et al.
Publicado: (2018)

A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer
por: Bauman, Julie E., et al.
Publicado: (2022)

More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY
por: Fleseriu, Maria, et al.
Publicado: (2021)

MON-309 Prevalence of Silent Corticotroph Adenomas in a Large Cohort of Nonfunctioning Pituitary Adenomas: Plasma Proopiomelanocortin(POMC) Levels and Response to Pasireotide LAR
por: Reyes-Vidal, Carlos, et al.
Publicado: (2020)

Long-term, real-world experience of pasireotide dose reduction in patients with acromegaly
por: Marques, Nelma Veronica, et al.
Publicado: (2023)

Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study
por: Bronstein, Marcello D., et al.
Publicado: (2016)

Impact of the diagnostic delay of acromegaly on bone health: data from a real life and long term follow-up experience
por: Chiloiro, Sabrina, et al.
Publicado: (2022)

Pasireotide: successful treatment of a sparsely granulated tumour in a resistant case of acromegaly
por: Amarawardena, W K M G, et al.
Publicado: (2017)

Evaluation of the Effects of Pasireotide LAR Administration on Lymphocele Prevention after Axillary Node Dissection for Breast Cancer: Results of a Randomized Non-Comparative Phase 2 Study
por: Chéreau, Elisabeth, et al.
Publicado: (2016)

Efficacy and safety of pasireotide-LAR for the treatment of refractory bleeding due to gastrointestinal angiodysplasias: results of the ANGIOPAS multicenter phase II noncomparative prospective double-blinded randomized study
por: Benamouzig, Robert, et al.
Publicado: (2018)

Medical Therapy with Pasireotide in Recurrent Cushing’s Disease: Experience of Patients Treated for At Least 1 Year at a Single Center
por: Yedinak, Chris G., et al.
Publicado: (2017)

Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease
por: Feelders, Richard A., et al.
Publicado: (2023)

Successful Therapy Using Pasireotide Long-acting Release for Cushing's Disease Merged with Biochemical Acromegaly
por: Fukunaga, Kensaku, et al.
Publicado: (2020)

Pasireotide for the Medical Management of Feline Hypersomatotropism
por: Scudder, C.J., et al.
Publicado: (2015)

Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, Phase II study
por: Boscaro, M., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_fae6o45fbnaeshsgs1sc8bshmo